In summary, gain-of-function mutations in Notch2 gene induce cardiac hypertrophy and diastolic dysfunction by disrupting ADSL-mediated AMP biosynthesis, and targeting purine nucleotide metabolism may represent an attractive therapeutic strategy for the treatment of cardiac diseases. This evidence concerns the gene NOTCH2 and cardiac hypertrophy.